Advertisement
U.S. markets close in 6 hours
  • S&P 500

    5,137.93
    -11.49 (-0.22%)
     
  • Dow 30

    38,856.69
    +66.26 (+0.17%)
     
  • Nasdaq

    15,994.60
    -108.85 (-0.68%)
     
  • Russell 2000

    2,018.57
    -6.17 (-0.30%)
     
  • Crude Oil

    82.98
    +0.26 (+0.31%)
     
  • Gold

    2,155.00
    -9.30 (-0.43%)
     
  • Silver

    25.06
    -0.20 (-0.81%)
     
  • EUR/USD

    1.0857
    -0.0020 (-0.18%)
     
  • 10-Yr Bond

    4.3160
    -0.0240 (-0.55%)
     
  • GBP/USD

    1.2698
    -0.0031 (-0.24%)
     
  • USD/JPY

    150.6540
    +1.5560 (+1.04%)
     
  • Bitcoin USD

    63,424.49
    -4,049.88 (-6.00%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,724.01
    +1.46 (+0.02%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Can Value Investors Consider Raymond James (RJF) Stock?

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Raymond James Financial, Inc. RJF stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Raymond James has a trailing twelve months PE ratio of 10.47, as you can see in the chart below:



This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 19.8. If we focus on the long-term PE trend, Raymond James’s current PE level puts it below its midpoint (which is 14.92) over the past five years. Moreover, the current level stands well below the highs for the stock, suggesting that it can be a solid entry point.



Further, the stock’s PE also compares favorably with the Zacks Finance sector’s trailing twelve months PE ratio, which stands at 12.99. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.



We should also point out that Raymond James has a forward PE ratio (price relative to this year’s earnings) of just 13.51, which is higher than the current level. So, it is fair to expect an increase in the company’s share price in the near term.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Raymond James has a P/S ratio of about 1.26. This is a bit lower than the S&P 500 average, which comes in at 3.58x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.



If anything, this suggests some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Raymond James currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Raymond James a solid choice for value investors, and some of its other key metrics make this pretty clear too.

What About the Stock Overall?

Though Raymond James might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of A. This gives RJF a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been sturdy at best. The current quarter has seen one estimates go higher in the past sixty days compared to none lower, while the full year estimate has seen one up and none down in the same time period.

This has had a noticeable impact on the consensus estimate though as the current quarter consensus estimate has surged by 61.4% in the past two months, while the full year estimate has increased by 12.3%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Raymond James Financial, Inc. Price and Consensus

Raymond James Financial, Inc. Price and Consensus
Raymond James Financial, Inc. Price and Consensus

Raymond James Financial, Inc. price-consensus-chart | Raymond James Financial, Inc. Quote

This somewhat favorable trend is why the stock has just a Zacks Rank #2 (Buy) and why we are looking for better performance from the company in the near term.

Bottom Line

Raymond James is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Further, a strong industry rank (among Top 31% of more than 250 industries) instills our confidence. However, over the past two years, the Zacks Financial - Investment Bank industry has clearly underperformed the broader market, as you can see below:



So, value investors might want to wait for analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Raymond James Financial, Inc. (RJF) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement